Trimetrexate
Alternative Names: CI 898; JB 11; Neutrexin; NSC 249008; NSC 328564; NSC 352122; Trimetrexate glucuronateLatest Information Update: 25 Sep 2021
At a glance
- Originator Pfizer
- Class Antineoplastics; Antiprotozoals; Quinazolines
- Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Pneumocystis pneumonia
- Discontinued Bladder cancer; Breast cancer; Cancer; Cervical cancer; Colorectal cancer; Gastric cancer; Leukaemia; Lung cancer; Non-small cell lung cancer; Pancreatic cancer; Psoriasis; Rheumatoid arthritis
Most Recent Events
- 14 Jan 2010 Biovitrum has merged with Swedish Orphan to form Swedish Orphan Biovitrum
- 19 Jun 2007 MedImmune has been acquired by AstraZeneca
- 05 Jun 2003 Beaufour-Ipsen is now called Ipsen